Mediware Ranks #1 For CPR+ and CareTend Software in Specialty Pharmacy Research Study

Mediware's picture
Printer-friendly versionPrinter-friendly version

CSI Specialty Group 2018 Research Report Indicates Providers Choose Mediware

LENEXA, Kan. — June 14, 2018 — Mediware Information Systems, Inc., a portfolio company of TPG Capital, is ranked as the #1 software provider for specialty pharmacy in CSI Specialty Group’s “2018 State of Specialty Pharmacy Report.” For the second consecutive year, Mediware’s CPR+ and CareTend clinical and business management solutions are recognized as the most widely used software systems among today’s specialty pharmacy providers.

Learn how CareTend ensures specialty pharmacy compliance today!

Learn More

CSI Specialty Group, a globally recognized, award-winning leadership consulting firm, released their latest data on the specialty pharmacy industry the end of last month. The research study surveyed independent specialty pharmacy professionals, manufacturers, and health systems to uncover current trends in the industry and the outlook for the coming months. Fifty percent of all providers surveyed reported that they currently use Mediware’s CPR+ and CareTend specialty pharmacy systems, ranking Mediware as the most-used software in the survey.

This ranking reaffirms our commitment to continuous innovation and excellence and ensures we can deliver value to our clients,” said Kimberly Commito, director of product management for Mediware. “Mediware’s technologies enable specialty pharmacies to better manage their businesses so they can expand the reach of their care and focus their impact on the communities they serve.”

“We are excited to release this year’s specialty pharmacy report findings, which indicate positive growth for the industry,” said Suzette DiMascio, president and CEO, CSI Specialty Group. “As the market continues to grow exponentially, it is vital that all stakeholders in this space work together to drive outcomes and improve patient care. We are happy to report that Mediware is the leading technology provider for this industry and that they are committed to driving value, outcomes, and success as a key partner in this dynamic market.”

Access the 2018 State of Specialty Pharmacy Report published by CSI Specialty Group at https://csigroup.net/survey/.

About Mediware

Mediware is a leading supplier of software for health care and human service providers and payers. Core Mediware solutions include blood management technologies for hospitals and blood centers; cell therapy solutions for cord blood banks, cancer treatment centers, and research facilities; medication management solutions for hospitals, behavioral health facilities, infusion and specialty pharmacy providers; and rehabilitation therapy and respiratory care solutions. For more information about Mediware products and services, visit our website at www.mediware.com.

About CSI Specialty Group

CSI Specialty Group is a globally recognized leadership consulting firm dedicated to providing solutions that continually elevate the specialty pharmacy industry and improve the patient journey. By providing inventive consulting, workforce planning and talent acquisition solutions, we uniquely tailor our service offerings to help clients drive sustainable, accelerated growth. For more information about CSI Specialty Group, visit www.CSIgroup.net.

About TPG

TPG is a leading global alternative asset firm founded in 1992 with more than $82 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com.

# # #

Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

18 + 0 =

To prevent automated spam submissions leave this field empty.